BioNTech (BNTX) Is Up 25.2% After First-in-Class Pumitamig Plus B7H3 ADC Lung Data – What's Changed

yf_tkr_BNTX · 2026-08-23 · Bullish AI sentiment

$BNTX $ADC

BioNTech SE has already presented new clinical data from its broad lung cancer pipeline at the 2026 IASLC World Conference on Lung Cancer in Seoul, covering key assets pumitamig, gotistobart and several mRNA-based immunotherapy approaches. The company’s first-in-class combination data pairing its PD-(L)1 x VEGF bispecific antibody pumitamig with a B7H3-targeted antibody-drug conjugate underscores BioNTech’s push into differentiated, novel-novel immunotherapy regimens in lung cancer. We’ll...

Read the original at yf_tkr_BNTX ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.